ACSL5 expression enhances tumor sensitivity to PD-1 blockade therapy in vivo and CD8 + T cell-mediated cytotoxicity in vitro by regulating major histocompatibility complex class I (MHC-I)-mediated antigen presentation [29]. The gene discussed is CD8A; the disease is neoplasm.